Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South America RNA-based Therapeutics Market

ID: MRFR/HC/50895-HCR
200 Pages
Nidhi Mandole
Last Updated: February 06, 2026

South America RNA-Based Therapeutics Market Research Report By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Application (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations), By Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South America RNA-based Therapeutics Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Pharmaceutical, BY Technology (USD Million)
  49.     4.1.1 RNA Interference
  50.     4.1.2 Antisense Oligonucleotides
  51.     4.1.3 mRNA Therapeutics
  52.     4.1.4 CRISPR Technology
  53.   4.2 Pharmaceutical, BY Application (USD Million)
  54.     4.2.1 Oncology
  55.     4.2.2 Infectious Diseases
  56.     4.2.3 Genetic Disorders
  57.     4.2.4 Cardiovascular Diseases
  58.   4.3 Pharmaceutical, BY End Use (USD Million)
  59.     4.3.1 Pharmaceutical Companies
  60.     4.3.2 Research Institutions
  61.     4.3.3 Contract Research Organizations
  62.   4.4 Pharmaceutical, BY Delivery Method (USD Million)
  63.     4.4.1 Liposomes
  64.     4.4.2 Nanoparticles
  65.     4.4.3 Viral Vectors
  66.     4.4.4 Electroporation
  67. 5 SECTION V: COMPETITIVE ANALYSIS
  68.   5.1 Competitive Landscape
  69.     5.1.1 Overview
  70.     5.1.2 Competitive Analysis
  71.     5.1.3 Market share Analysis
  72.     5.1.4 Major Growth Strategy in the Pharmaceutical
  73.     5.1.5 Competitive Benchmarking
  74.     5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  75.     5.1.7 Key developments and growth strategies
  76.       5.1.7.1 New Product Launch/Service Deployment
  77.       5.1.7.2 Merger & Acquisitions
  78.       5.1.7.3 Joint Ventures
  79.     5.1.8 Major Players Financial Matrix
  80.       5.1.8.1 Sales and Operating Income
  81.       5.1.8.2 Major Players R&D Expenditure. 2023
  82.   5.2 Company Profiles
  83.     5.2.1 Moderna (US)
  84.       5.2.1.1 Financial Overview
  85.       5.2.1.2 Products Offered
  86.       5.2.1.3 Key Developments
  87.       5.2.1.4 SWOT Analysis
  88.       5.2.1.5 Key Strategies
  89.     5.2.2 BioNTech (DE)
  90.       5.2.2.1 Financial Overview
  91.       5.2.2.2 Products Offered
  92.       5.2.2.3 Key Developments
  93.       5.2.2.4 SWOT Analysis
  94.       5.2.2.5 Key Strategies
  95.     5.2.3 Alnylam Pharmaceuticals (US)
  96.       5.2.3.1 Financial Overview
  97.       5.2.3.2 Products Offered
  98.       5.2.3.3 Key Developments
  99.       5.2.3.4 SWOT Analysis
  100.       5.2.3.5 Key Strategies
  101.     5.2.4 Ionis Pharmaceuticals (US)
  102.       5.2.4.1 Financial Overview
  103.       5.2.4.2 Products Offered
  104.       5.2.4.3 Key Developments
  105.       5.2.4.4 SWOT Analysis
  106.       5.2.4.5 Key Strategies
  107.     5.2.5 Sangamo Therapeutics (US)
  108.       5.2.5.1 Financial Overview
  109.       5.2.5.2 Products Offered
  110.       5.2.5.3 Key Developments
  111.       5.2.5.4 SWOT Analysis
  112.       5.2.5.5 Key Strategies
  113.     5.2.6 CureVac (DE)
  114.       5.2.6.1 Financial Overview
  115.       5.2.6.2 Products Offered
  116.       5.2.6.3 Key Developments
  117.       5.2.6.4 SWOT Analysis
  118.       5.2.6.5 Key Strategies
  119.     5.2.7 Arcturus Therapeutics (US)
  120.       5.2.7.1 Financial Overview
  121.       5.2.7.2 Products Offered
  122.       5.2.7.3 Key Developments
  123.       5.2.7.4 SWOT Analysis
  124.       5.2.7.5 Key Strategies
  125.     5.2.8 Translate Bio (US)
  126.       5.2.8.1 Financial Overview
  127.       5.2.8.2 Products Offered
  128.       5.2.8.3 Key Developments
  129.       5.2.8.4 SWOT Analysis
  130.       5.2.8.5 Key Strategies
  131.   5.3 Appendix
  132.     5.3.1 References
  133.     5.3.2 Related Reports
  134. 6 LIST OF FIGURES
  135.   6.1 MARKET SYNOPSIS
  136.   6.2 SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
  137.   6.3 SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  138.   6.4 SOUTH AMERICA MARKET ANALYSIS BY END USE
  139.   6.5 SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD
  140.   6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
  141.   6.7 RESEARCH PROCESS OF MRFR
  142.   6.8 DRO ANALYSIS OF PHARMACEUTICAL
  143.   6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
  144.   6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
  145.   6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
  146.   6.12 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
  147.   6.13 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
  148.   6.14 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
  149.   6.15 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
  150.   6.16 PHARMACEUTICAL, BY END USE, 2024 (% SHARE)
  151.   6.17 PHARMACEUTICAL, BY END USE, 2024 TO 2035 (USD Million)
  152.   6.18 PHARMACEUTICAL, BY DELIVERY METHOD, 2024 (% SHARE)
  153.   6.19 PHARMACEUTICAL, BY DELIVERY METHOD, 2024 TO 2035 (USD Million)
  154.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  155. 7 LIST OF TABLES
  156.   7.1 LIST OF ASSUMPTIONS
  157.     7.1.1
  158.   7.2 South America MARKET SIZE ESTIMATES; FORECAST
  159.     7.2.1 BY TECHNOLOGY, 2025-2035 (USD Million)
  160.     7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  161.     7.2.3 BY END USE, 2025-2035 (USD Million)
  162.     7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Million)
  163.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  164.     7.3.1
  165.   7.4 ACQUISITION/PARTNERSHIP
  166.     7.4.1

South America Pharmaceutical Market Segmentation

Pharmaceutical By Technology (USD Million, 2025-2035)

  • RNA Interference
  • Antisense Oligonucleotides
  • mRNA Therapeutics
  • CRISPR Technology

Pharmaceutical By Application (USD Million, 2025-2035)

  • Oncology
  • Infectious Diseases
  • Genetic Disorders
  • Cardiovascular Diseases

Pharmaceutical By End Use (USD Million, 2025-2035)

  • Pharmaceutical Companies
  • Research Institutions
  • Contract Research Organizations

Pharmaceutical By Delivery Method (USD Million, 2025-2035)

  • Liposomes
  • Nanoparticles
  • Viral Vectors
  • Electroporation

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓